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Abstract
Background: Improved treatment of congenital heart defects (CHDs) has increased survival of 
persons with CHDs; however, no U.S. population-based systems exist to assess prevalence, 
healthcare utilization, or longer-term outcomes among adolescents and adults with CHDs.
Methods: Novel approaches identified individuals aged 11–64 years who received healthcare 
with ICD-9-CM codes for CHDs at three sites: Emory University in Atlanta, Georgia (EU), 
Massachusetts Department of Public Health (MA), New York State Department of Health (NY) 
between January 1, 2008 (2009 for MA) and December 31, 2010. Case-finding sources included 
outpatient clinics; Medicaid and other claims data; and hospital inpatient, outpatient, and 
emergency visit data. Supplemental information came from state vital records (EU, MA), and birth 
defects registries (EU, NY). Demographics and diagnostic and procedural codes were linked, de-
duplicated, and shared in a de-identified dataset. Cases were categorized into one of five mutually 
exclusive CHD severity groups; non-cardiac comorbidity codes were grouped into broad 
categories.
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Results: 73,112 individuals with CHD codes in healthcare encounters were identified. Primary 
data source type varied: clinics (EU, NY for adolescents), claims (MA), hospital (NY for adults). 
There was a high rate of missing data for some variables and data varied in format and quality. 
Some diagnostic codes had poor specificity for CHD ascertainment.
Conclusions: To our knowledge, this is the first population-based, multi-site CHD surveillance 
among adolescents and adults in the U.S. Identification of people living with CHDs through 
healthcare encounters using multiple data sources was feasible, though data quality varied and 
linkage/de-duplication was labor-intensive.
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1 | INTRODUCTION
Congenital heart defects (CHDs) affect about 1% of U.S. births and are a leading cause of 
birth defect-associated infant mortality, morbidity, and healthcare costs (Arth et al., 2017; 
Botto, Correa, & Erickson, 2001; Hoffman & Kaplan, 2002; Rosano, Botto, Botting, & 
Mastroiacovo, 2000; Simeone et al., 2015; Yang et al., 2006; Yoon et al., 1997). Improved 
treatment of CHDs has resulted in many individuals, even those with severe types of CHDs, 
living into adolescence and adulthood. (Gilboa et al., 2016; Hoffman, Kaplan, & Liberthson, 
2004; Marelli et al., 2014; Marelli, Mackie, Ionescu-Ittu, Rahme, & Pilote, 2007; Marelli, 
Therrien, Mackie, Ionescu-Ittu, & Pilote, 2009; Pillutla, Shetty, & Foster, 2009; Warnes et 
al., 2001) Birth defects surveillance systems in 42 states estimate the birth prevalence of 
many types of CHDs. However, there are no existing population-based systems in the U.S. to 
estimate prevalence beyond early childhood, or to assess the healthcare utilization and 
longer-term outcomes among adolescents and adults with CHDs. Based on extrapolated 
Canadian data, an estimated one million children and 1.4 million adults in the U.S. were 
living with a CHD in 2010, of whom approximately 12%, or 289,000 had a severe CHD 
(Gilboa et al., 2016).
The Centers for Disease Control and Prevention (CDC) funded three sites (Emory University 
[EU] in Atlanta, Georgia; Massachusetts Department of Public Health [MA]; and New York 
State Department of Health [NY]) for a surveillance project to better understand the 
prevalence, healthcare utilization, and longer-term outcomes of adolescents and adults with 
CHDs. This article describes the surveillance methodology. The participating sites had 
varying populations and data sources, completeness, and linkage methodologies. Project 
elements that were consistent among sites are described first, followed by unique site-
specific methodology.
2 | OVERALL PROJECT METHODOLOGY
2.1 | Target population
Eligible cases resided in site-specific catchment areas and were aged 11 through 64 years at 
any time between January 1, 2008 and December 31, 2010 (January 1, 2009 and December 
31, 2010 for MA). Catchment areas were statewide (MA) or county-specific (EU, NY). 
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Eligible cases were presumed to be alive as of January 1, 2010, and had a healthcare 
encounter between January 1, 2008 and December 31, 2010 (January 1, 2009 and December 
31, 2010 for MA) which was captured in one of the data sources. Each site determined vital 
status by linking to state death certificates, the absence of which presumed, but did not 
verify, living status.
2.2 | Surveillance case definition
Cases were identified using International Classification of Disease, Ninth Revision, Clinical 
Modification (ICD-9-CM) CHD diagnostic codes 745.xx–747.xx, excluding: congenital 
heart block (746.86), pulmonary arteriovenous malformation (747.32), absent/hypoplastic 
umbilical artery (747.5), other anomalies of peripheral vascular system (747.6x), and other 
specified anomalies of circulatory system (747.8x). For data sources using other coding 
systems, the sites converted all codes to ICD-9-CM.
The remaining eligible CHD codes were categorized into five hierarchical groups similar to 
Marelli et al. (2007), integrating both hemodynamic severity and basic anatomy: severe, 
shunt plus valve, shunt, valve, and other CHDs (Table 1). Several codes were classified as 
“minor” CHD (Table 1). Severe CHD was defined as a CHD usually requiring surgical or 
catheter intervention within the first year of life. For CHDs with variable severity (e.g., 
aortic stenosis), case-specific severity could not be distinguished using administrative 
ICD-9-CM coding. All unique CHD codes were reported for each case. Cases were 
classified into one of the five mutually exclusive CHD groups according to a severity 
algorithm (Figure 1). Study clinicians determined a set of minor codes (Table 1) which were 
nonspecific (e.g., 746.9 unspecified defect of heart), usually associated with another CHD 
(e.g., 747.3 anomalies of pulmonary artery), or which may be an incidental or non-
congenital finding (e.g., valve insufficiency). Cases with isolated minor codes were reported; 
otherwise, minor codes were not utilized in case classification (Figure 1).
2.3 | Surveillance data elements
Cases could have multiple healthcare encounters in multiple data sources. For each 
healthcare encounter, the following information was collected, when available: 
demographics, type of data source, coding system, encounter date, encounter type, length of 
stay (for hospitalizations), all ICD-9-CM and current procedural terminology (CPT) codes 
(diagnoses and procedures), and death-related variables. All data elements were defined by 
the collaborative group and standardized across sites.
ICD-9-CM codes unrelated to CHD diagnoses and all CPT codes were grouped into 
categories of comorbidities and procedures using the clinical classification software (CCS) 
tool, developed by the Agency for Healthcare Research and Quality (Healthcare Cost and 
Utilization Project, 2016). Non-cardiac diagnostic CCS categories were collapsed into 24 
broader comorbidity groups for this project (Supporting Information Table 1). The codes in 
the cardiac- and vascular-related procedural CCS categories were collapsed into the 
following project-specific cardiac procedure categories: cardiac procedures and surgeries, 
diagnostic imaging, and vascular procedures (Supporting Information Table 2). Procedural 
codes not specified in these categories were considered non-cardiac procedures. Cases were 
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reported as having a non-cardiac procedure (e.g., knee replacement [yes/no]); the specific 
non-cardiac procedural codes were not reported.
2.4 | Data collection, cleaning, and linkage
Data use agreements were initiated and managed by sites for each data source. Data sources 
provided data to each site based on the case definition and variable list. After a case was 
identified with an eligible CHD code, data from all available encounters during the 
surveillance time period were extracted. Data varied in format and content, often requiring 
extensive standardization and verification of eligibility. Values were checked for permissible 
ranges, and data from all sources were used to supplement missing data. Multiple case 
encounters were de-duplicated and linked within and across data sources. Further linkage 
details are described in the site-specific methodologies.
2.5 | CHD code validation
Studies have shown that ICD-9-CM codes for CHDs lack specificity and have poor 
diagnostic accuracy. (Cronk et al., 2003; Frohnert et al., 2005; Strickland et al., 2008; 
Rodriguez et al., 2018) For example, 745.5 codes for both atrial septal defect (ASD), a true 
CHD, and patent foramen ovale (PFO), a normal newborn condition. The PFO, which may 
persist in 25% of adults, is usually clinically insignificant and asymptomatic, but potentially 
associated with strokes. The 745.4 codes for ventricular septal defect, a common congenital 
condition which may also be acquired in adults after a myocardial infarction. To investigate 
the validity of specific codes for identifying a true CHD, clinicians at participating sites 
reviewed medical records from a random sample of cases. Each site had different sample 
size and code selection (Table 2) based on number of cases with codes of interest, 
availability of medical records, and clinical review resources. Cases sampled had the 
following isolated codes potentially used for non-CHD conditions: 745.5, 745.4 in persons 
>40 years old, 746.85 (coronary artery anomaly), and 746.89/746.9 (other specified/
unspecified heart anomaly).
3 | SITE-SPECIFIC METHODOLOGY
3.1 | Emory University
EU collected data statewide, but only reported data from five metropolitan Atlanta counties: 
Clayton, Cobb, DeKalb, Fulton, and Gwinnett for the final dataset, which was more 
saturated with healthcare institutions providing care to CHD patients. The source population 
was approximately 2,404,907 individuals and was racially diverse. Cases were identified 
from statewide Georgia (GA) Medicaid claims and from six clinical data sources: Emory 
Healthcare (EHC) (two large and multiple smaller hospitals, with affiliated outpatient 
multispecialty practices), St. Joseph’s Hospital, a large, urban two-county safety net 
healthcare system (inpatient and outpatient) serving a large portion of socioeconomically 
disadvantaged people, a children’s hospital system (includes three hospitals and affiliated 
outpatient multispecialty practices), and two pediatric cardiology private practices that 
collectively provide more than 90% of pediatric cardiology care in Georgia. GA Vital 
Records and CDC’s Metropolitan Atlanta Congenital Defects Program (MACDP) provided 
supporting information on cases that were identified elsewhere. GA birth certificates 
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provided demographic information, and death certificates confirmed deaths, identified 
deaths not found in other sources, and provided additional death information. Data de-
duplication and linkage was performed within and across data sources by deterministic 
matching of identifiers [name, date of birth, gender, Social Security Number (SSN), medical 
record number]. All discrepancies were individually reviewed and resolved. Linkages were 
continually updated as new data were obtained.
3.2 | Massachusetts Department of Public Health
MA’s catchment area was statewide with a racially diverse source population of 
approximately 4,818,851 individuals. The largest case-finding data source was the 
Massachusetts All-Payer Claims Database (MA APCD). MA APCD includes medical 
claims, member demographics, insurance information and provider information submitted 
by over 100 payers including commercial payers, third party administrators, and public 
programs (Medicare HMOs and MassHealth, Massachusetts’ Medicaid program). The MA 
APCD does not include claims or information on individuals covered by Workers’ 
Compensation, TRICARE or the Veterans Health Administration, the Federal Employees 
Health Benefit Plan, private insurers with fewer than 1,000 individuals covered, or uninsured 
individuals not enrolled in the Commonwealth’s health safety net. Because of the high level 
of insurance coverage in MA (~96%), the MA APCD is estimated to include about 90% of 
state residents. (Massachusetts Health Insurance, 2013) MA APCD data were unavailable 
prior to 2009; therefore, MA collected 2009–2010 data for this project. Additional case 
finding sources were two large tertiary care referral centers serving the metropolitan Boston 
area and two smaller tertiary care centers in Central and Western Massachusetts. Identified 
cases were linked to MA electronic birth files, available from 1969 onward, and electronic 
death files. Records were de-duplicated within data source using a set of identifiers (last 
name, first name, date of birth, gender). Records were linked across data sources using 
FRIL’s (Fine-Grained Records Integration and Linkage Tool), v. 2.1.5 (Jurczyk, Lu, Xiong, 
Cragan, & Correa, 2008).
3.3 | New York State Department of Health
NY’s catchment area was 11 counties: Allegany, Bronx, Cattaraugus, Chautauqua, Erie, 
Genesee, Monroe, Niagara, Orleans, Westchester, and Wyoming. The source population was 
approximately 3,346,037 individuals, was racially diverse, and included both rural and 
metropolitan areas. A major case-finding and data source for cases of all ages in NY was the 
Statewide Planning and Research Cooperative System (SPARCS). SPARCS is a 
comprehensive, integrated information system available for healthcare resource planning, 
cost analysis, and surveillance of the state hospital services. Implemented by the New York 
State Department of Health (NYSDOH) in 1979, SPARCS receives hospital inpatient and 
outpatient discharge data from all facilities in NY. Adult cases (aged 20–64 years) were only 
identified through SPARCS; adolescent cases (aged 11–19 years) were also identified from 
seven pediatric cardiology healthcare facilities in and adjacent to the catchment area. These 
facilities provide a broad range of care for adolescents with CHDs, including cardiac 
surgeries and advanced treatment of complex CHDs. The NYSDOH’s Congenital 
Malformations Registry (CMR), a state-mandated reporting system for children in NY with 
birth defects diagnosed under the age of 2 years, provided supporting information on 
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adolescent cases identified elsewhere. CMR data are routinely matched to birth and death 
certificate files using deterministic data linkage methods. NY was unable to link directly to 
vital statistics records. Only CMR data linked to death certificates and SPARCS discharge 
status were used to determine case vital status as of January 1, 2010. Records were de-
duplicated within data source using all available identifiers (name, date of birth, address, 
SSN, medical record number, patient account number). The cases were then matched across 
data sources using FRIL v2.1.5 (Jurczyk et al., 2008) and SAS v9.3 (SAS Institute Inc., 
Cary, NC). Due to limited name information available in SPARCS data, the first two letters 
of the first name and the first two and last two letters of the last name were used for 
matching. A different matching weight was assigned for each variable, and matching was 
considered successful if 90% of information was matched, matching two data sources at a 
time. All variable and encounter data was combined with the unique linked and de-
duplicated case.
3.4 | Surveillance dataset
Each site’s Institutional Review Board approved sharing of de-identified data with the CDC. 
A Microsoft Access database was developed collaboratively with CDC and participating 
sites to house standardized data. De-identified, de-duplicated data, which combined and 
reconciled information from multiple data sources, were transmitted to CDC via a secure 
mechanism.
4 | RESULTS
Participating sites had varying populations and data sources, completeness, and linkage 
methodologies. However, all three sites linked and de-duplicated cases within and across 
multiple, existing datasets. A total of 73,112 unique individuals, aged 11–64 years, were 
identified who were presumed to be alive as of January 1, 2010, and who had an ICD-9-CM 
code for a CHD during healthcare encounters in the catchment areas (5,203 in EU, 62,605 in 
MA, 5,304 in NY). Overall, cases in MA were older (mean age = 37.1 years, median age = 
38.0 years) compared to EU (mean = 30.5, median = 25.0) and NY (mean = 30.8, median = 
22.0). Regarding case severity, shunts were the largest category at all sites. EU had a higher 
percentage of cases with “severe” CHDs and MA had a higher percentage of cases with 
“other” CHDs, relative to the other two sites (Figure 2). Subsequent papers will describe 
prevalence and characteristics of adolescents, adults, and pregnant women by surveillance 
site.
Each site had different amounts of cases found in each type of data source and across 
multiple data sources (Figure 3). The majority of EU and NY adolescent cases were found in 
clinics (75% and 81%, respectively) compared to only 10% of MA cases. NY did not use 
clinic data for adult case finding. Across all sites, <10% of cases were found in more than 
one case-finding data source. For example, of the 2,537 NY adolescent cases, only 42 
(1.7%) were found in all three case-finding data sources. Conversely, 94% (EU), 93% (MA), 
87% (NY adolescent) and 92% (NY adult) cases were found in a single data source (Figure 
3).
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Despite using multiple data sources for case-finding and supplemental information, sites had 
different amounts of missing demographic information (Table 2). Age, birth year, and 
gender were nearly always available; however, race was missing from 32% (EU), 48% 
(MA), and 20% (NY), body weight missing from approximately 90% of cases in all sites 
(Table 2). No data was available on employment status, education level, enrollment in 
special education, and receipt of social security income.
Results of site-specific case review for code validity are shown in Table 3. For a sample of 
cases identified with ICD-9-CM code 745.5, true CHD status varied from 24–59%. Thus, 
certain analyses from this project may report cases with isolated 745.5 separately due to the 
probability of misclassification. At EU, the majority of sampled cases with the other codes 
truly had a CHD. However, most cases sampled in NY with nonspecific or other specified 
codes (746.89/746.9) did not actually have a CHD (Table 3).
5 | DISCUSSION
This surveillance project used novel approaches to identify individuals who had healthcare 
encounters with ICD-9-CM codes for CHDs using multiple existing data sources. All sites 
were able to identify, link and de-duplicate cases within and across data sources, and collect 
demographics, clinical information, and healthcare utilization for characterization of 
adolescents and adults living with CHDs. Despite heterogeneity of surveillance 
methodology, there was similar distribution of case severity across the sites, which may be 
characteristic of the CHD population seeking healthcare or the entire CHD population. The 
case-finding methods used in MA identified many more individuals living with CHDs than 
the other sites. This may be result of differences in methodology, for example, coding 
practices; data sources and source population; healthcare access; geography; or other factors.
Data sources varied across sites in data quality, completeness, population, availability and 
accessibility. Even within a type (e.g., administrative claims) each site varied, depending on 
healthcare systems and policies. For example, APCD and SPARCS are not available in all 
states. Therefore, cases captured through healthcare encounters will vary based on data 
source availability in regions or states. There are advantages and disadvantages to all types 
of data sources. Advantages of clinical data are their detailed diagnostic, treatment, and 
clinical outcome information; limitations include capturing select cases, which may not be 
representative of the population, small sample size, and may not include healthcare 
utilization. Administrative claims data have large sample size and detailed healthcare 
utilization information; limitations include missing cases not receiving healthcare, coding 
systems that do not sufficiently specify types of CHDs or procedures, and potential 
inaccuracies in coding (Riehle-Colarusso et al., 2016).
There were several methodological strengths of this pilot surveillance project. First, this was 
the development of a case definition that utilized an existing hierarchical structure (Marelli 
et al., 2007) tailored to include the coding structure of the data sources. The case definition 
developed is specific to CHDs, excludes non-cardiac defects, and stratifies cases into 
mutually exclusive CHD severity categories. Another strength is the fact that the sites 
leveraged some data sources in which CHD diagnoses were already confirmed by clinical 
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experts in cardiology. Using data from these cardiac clinical care facilities increased the 
percentage of cases that were accurately coded. Finally, since 90% of cases were found in 
only one data source, it was clear that using multiple types of data sources increases the 
quantity and breadth of case ascertainment.
Data from this surveillance project should be viewed in light of several limitations. Persons 
with CHDs who did not have a healthcare encounter or have the CHD documented in their 
medical record during the target period were not identified. The likelihood of having a 
healthcare encounter could be affected by factors such as health insurance coverage, which 
differed considerably across the three sites. Second, limitations exist in using administrative 
ICD-9-CM codes for case inclusion. Although using clinical data sources might increase 
coding accuracy, variability in coding practices across the three geographic regions revealed 
differences in the number, choice, and consistency in code utilization. In addition, the use of 
ICD-9-CM codes may misclassify cases, for example, 745.5 is often used in adults to code 
for the normal anatomic variant, PFO, which would result in misclassification and an 
overestimation of cases with a CHD (Rodriguez et al., 2018), which would result in 
misclassification and an overestimation of cases with a CHD. Due to resource limitations, a 
uniform, extensive code validation across the three sites was not done.
There were several implementation challenges during this project. First, establishing 
partnerships and access to the data was time-consuming, taking nearly 18 months of the 3-
year project period. Second, electronic health records were not uniformly implemented 
during the study period and data obtained varied in completeness and quality, leading to 
much time spent on cleaning for inclusion in the final dataset. Third, depending on the 
availability and completeness of matching variables, the linkage process was labor-intensive. 
Many demographic variables were missing, making de-duplicating individuals identified 
from multiple data sources challenging. Despite multiple data sources, basic variables such 
as race, height, and weight were missing at a significant rate at all sites. Finally, as national 
death records were not used to verify vital status, due to resource limitations, the absence of 
linkage to a state death record only presumes but does not verify that the individual was 
alive as of January 1, 2010.
This is the first step in gathering empiric data to understand the prevalence of CHDs beyond 
infancy in the United States, and in developing an approach to monitoring trends and 
regional variations. This surveillance project shows the importance of using multiple sources 
to conduct surveillance of individuals with CHDs. It is also important to note that 
individuals with an ICD-9-CM CHD-coded healthcare encounter are only a portion of the 
total population. During a predefined surveillance time period, eligible individuals with 
CHD may not seek health care or may not have a CHD recorded during a healthcare 
encounter. Having an estimate of the number and characteristics of adolescents and adults 
living with CHDs can provide important information to parents receiving a diagnosis of a 
CHD in their newborn child. This information may also be useful to public health 
professionals, policy-makers, and healthcare providers in planning resources and 
interventions for individuals living with CHDs.
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FIGURE 1. 
Congenital heart defect case classification algorithm
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FIGURE 2. 
Percentage of cases by site and congenital heart defect severity group
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FIGURE 3. 
Data sources and CHD case ascertainment by site. †Statewide Planning and Research 
Cooperative System
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